With the advance of cancer therapy in recent years, the knowledge of the mechanisms involved in this disease has increased, which has meant an increase in the quality of life and survival of patients with tumor pathologies previously considered incurable or refractory to treatment. The number of drugs used has increased exponentially in number, and although the implicit toxicity is lower than that of conventional antineoplastic therapy, they lead to the appearance of new associated adverse effects that the ophthalmologist must recognize and manage.
Keywords: Anticuerpo monoclonal; Chemotherapy; Efecto secundario; Monoclonal antibody; Pequeñas moléculas; Quimioterapia; Side effect; Small molecules; Targeted therapy; Terapia dirigida.
Copyright © 2023 Sociedad Española de Oftalmología. Published by Elsevier España, S.L.U. All rights reserved.